Diagnos Laboratorium (Indonesia) Performance
| DGNS Stock | IDR 220.00 4.00 1.79% |
The firm shows a Beta (market volatility) of -0.82, which means possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Diagnos Laboratorium are expected to decrease at a much lower rate. During the bear market, Diagnos Laboratorium is likely to outperform the market. At this point, Diagnos Laboratorium has a negative expected return of -0.46%. Please make sure to confirm Diagnos Laboratorium's coefficient of variation, jensen alpha, and the relationship between the mean deviation and standard deviation , to decide if Diagnos Laboratorium performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Diagnos Laboratorium Utama has generated negative risk-adjusted returns adding no value to investors with long positions. Despite conflicting performance in the last few months, the Stock's forward-looking signals remain quite persistent which may send shares a bit higher in December 2024. The latest mess may also be a sign of long-standing up-swing for the company institutional investors. ...more
| Total Cashflows From Investing Activities | -75.6 B |
Diagnos |
Diagnos Laboratorium Relative Risk vs. Return Landscape
If you would invest 30,800 in Diagnos Laboratorium Utama on September 1, 2024 and sell it today you would lose (8,800) from holding Diagnos Laboratorium Utama or give up 28.57% of portfolio value over 90 days. Diagnos Laboratorium Utama is generating negative expected returns and assumes 3.522% volatility on return distribution over the 90 days horizon. Simply put, 31% of stocks are less volatile than Diagnos, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Diagnos Laboratorium Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Diagnos Laboratorium's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Diagnos Laboratorium Utama, and traders can use it to determine the average amount a Diagnos Laboratorium's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1314
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | DGNS |
Estimated Market Risk
| 3.52 actual daily | 31 69% of assets are more volatile |
Expected Return
| -0.46 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.13 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Diagnos Laboratorium is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Diagnos Laboratorium by adding Diagnos Laboratorium to a well-diversified portfolio.
Diagnos Laboratorium Fundamentals Growth
Diagnos Stock prices reflect investors' perceptions of the future prospects and financial health of Diagnos Laboratorium, and Diagnos Laboratorium fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Diagnos Stock performance.
| Return On Equity | 0.0603 | |||
| Return On Asset | 0.0297 | |||
| Profit Margin | 0.06 % | |||
| Operating Margin | 0.06 % | |||
| Current Valuation | 967.86 B | |||
| Shares Outstanding | 1.25 B | |||
| Price To Earning | 10.49 X | |||
| Price To Sales | 1.60 X | |||
| Revenue | 302.18 B | |||
| EBITDA | 19.21 B | |||
| Cash And Equivalents | 52.8 B | |||
| Cash Per Share | 42.24 X | |||
| Total Debt | 10.45 B | |||
| Debt To Equity | 0.01 % | |||
| Book Value Per Share | 171.17 X | |||
| Cash Flow From Operations | 58.87 B | |||
| Earnings Per Share | 51.84 X | |||
| Total Asset | 241.98 B | |||
About Diagnos Laboratorium Performance
By examining Diagnos Laboratorium's fundamental ratios, stakeholders can obtain critical insights into Diagnos Laboratorium's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Diagnos Laboratorium is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
PT Diagnos Laboratorium Utama Tbk provides health services using laboratories. The company was founded in 2007 and is headquartered in Jakarta Pusat, Indonesia. Diagnos Laboratorium operates under Diagnostics Research classification in Indonesia and is traded on Jakarta Stock Exchange. It employs 406 people.Things to note about Diagnos Laboratorium performance evaluation
Checking the ongoing alerts about Diagnos Laboratorium for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Diagnos Laboratorium help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Diagnos Laboratorium generated a negative expected return over the last 90 days | |
| Diagnos Laboratorium has high historical volatility and very poor performance | |
| About 80.0% of the company shares are held by company insiders |
- Analyzing Diagnos Laboratorium's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Diagnos Laboratorium's stock is overvalued or undervalued compared to its peers.
- Examining Diagnos Laboratorium's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Diagnos Laboratorium's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Diagnos Laboratorium's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Diagnos Laboratorium's stock. These opinions can provide insight into Diagnos Laboratorium's potential for growth and whether the stock is currently undervalued or overvalued.
Other Information on Investing in Diagnos Stock
Diagnos Laboratorium financial ratios help investors to determine whether Diagnos Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Diagnos with respect to the benefits of owning Diagnos Laboratorium security.